Number of Orphan Medicines to Grow in Europe as ‘Big Pharma’ Takes an Interest Says New Report from URCH Publishing  
12/9/2011 6:25:11 AM

LONDON--(BUSINESS WIRE)--The number of medicines designated and marketed with an orphan status will grow steadily in Europe says a new report. Orphan Drug Markets in Europe - Key developments and the strategies of major pharmaceutical companies published by URCH Publishing, a business information provider, says that the commercial success of many orphans over the last ten years is boosting interest from Big Pharma as their blockbuster model becomes unsustainable. Already a number of major companies have reassessed their strategy with respect to orphan drugs and five of the top ten have made explicit commitments to the development of such drugs.